Cidara Therapeutics is a biotechnology company based in San Diego that focuses on developing long-acting antiviral and anti-infective therapies. The company uses a special platform to create drugs that combine antiviral molecules with antibody fragments, aiming to provide stronger and longer protection against infections. One of its main products in development, CD388, targets influenza viruses and is designed to work as a single seasonal shot. Cidara is also working on treatments for other serious infections and diseases. The company’s goal is to offer new options for people at high risk, including those who cannot use traditional vaccines or treatments.